CGEM Stock Recent News

Taiho Pharmaceutical Co Ltd will co-develop and co-commercialize Cullinan Oncology Inc (NASDAQ: CGEM) lead program, CLN-081/TAS6417. Under the agreement, Taiho will acquire Cullinan Oncology's subsidiary, Cullinan Pearl, which has worldwide rights outside of Japan to CLN-081/.